New Biomarker Could Lead To The World's First Reliable Test For Liver Cancer

Apr 09, 2010

(PhysOrg.com) -- Liver cancer is the fifth most common cancer in the world and one of the deadliest cancers since it is rarely diagnosed until late in its development.

The lack of reliable screening tests for liver cancer contributes to its high mortality rate since tumors seldom cause symptoms until the later stages when treatment options become limited and the prognosis is poorer. Death usually occurs not long after diagnosis.

But that might be about to change, according to Dr. Claus Fimmel, a hepatologist who is involved in an international study of a protein that is shaping up as a promising basis for the development of an effective liver-cancer screening test for high-risk patients.

"The protein pretty reliably shows up in the blood of patients with liver cancer in several studies from Europe, China and the United States," said Fimmel, who is division director of gastroenterology, and nutrition at Loyola University Medical Center in Maywood. "We're very excited about its prospects."

The current blood test used to screen for early tumors in people at high risk for liver cancer involves a protein called alpha-fetoprotein (AFP), Fimmel said. Patients who are at risk for liver cancer typically have such as cirrhosis due to infection with the or C virus or alcoholism.

"Unfortunately, the AFP test is not good enough to detect liver cancer in time, and it often generates a false positive in patients who end up not having the cancer," Fimmel said.

The protein being studied is known as Golgi Protein-73 (GP73), which was first discovered in Dr. Fimmel’s lab in 1998. Subsequent studies have shown that the blood levels of GP73 are consistently higher in patients with liver cancer than in healthy individuals. In addition, levels were not significantly higher in patients with diseases other than liver disease.

“If you stumble upon something that interesting from a basic science point of view but that has potential practical value for early diagnosis, it's very gratifying,” Fimmel said. "We're on the verge of understanding what switches GP73 on and how we can use it for diagnostic purposes."

For far, the blood samples of more than 1,000 patients with various stages of liver and non-liver disease have been tested for the presence of GP73 in several studies around the world. Several medical diagnostic companies are in the process of developing automated serum tests for the protein that could be performed in routine hospital laboratories.

"GP73 is currently being test in clinical trials in a couple of places. The biggest study is being done in China where liver cancer is very common due to the large numbers of people infected with hepatitis B," Fimmel said.

With the large number of Americans infected with hepatitis C, the number of people developing cirrhosis in the United States is expected to rise during the next 20 years.

"If you have cirrhosis, each year you have a 1 to 2 percent higher chance of developing liver cancer. Each year it goes up a notch," Fimmel said. "Consequently, a person has as much as a 20 percent risk for developing after having cirrhosis for 20 years."

Explore further: Study finds a new approach to tackle drug resistance in hematologic malignancies

add to favorites email to friend print save as pdf

Related Stories

New test improves detection of liver cancer

Aug 08, 2007

Cancer of the liver is very difficult to detect, and it is a major cause of death in Asia and Africa, with rising incidence in Western countries as well. Now, VIB researchers connected to Ghent University, in collaboration ...

Molecules may help predict survival in liver cancer

Jan 30, 2008

Tiny molecules that help cells regulate which proteins they make might one day help doctors predict which liver-cancer patients are likely to live longer than others, new research suggests.

Recommended for you

XenOPAT, mouse models for personalized cancer treatment

1 hour ago

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

Gene linked to development of skin cancer in mice

3 hours ago

(Medical Xpress)—New research on an enzyme linked to cancer development shows that 37 percent of mice that produce excessive quantities of the enzyme developed skin tumors within four to 12 months of birth, ...

User comments : 0